Ignite Creation Date:
2024-05-06 @ 8:36 AM
Last Modification Date:
2024-10-26 @ 12:02 PM
Study NCT ID:
NCT02773849
Status:
COMPLETED
Last Update Posted:
2023-12-22
First Post:
2016-04-19
Brief Title:
ADSTILADRIN INSTILADRIN in Patients With High-Grade Bacillus Calmette-Guerin BCG Unresponsive Non-Muscle Invasive Bladder Cancer NMIBC
Sponsor:
Organization:
Ferring Pharmaceuticals
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
157
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE3 |
Observational Models:
Time Perspective List:
Who Masked List: